{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:50:17Z","timestamp":1793343017900,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00228-025-03900-z","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T04:18:05Z","timestamp":1755490685000},"page":"1659-1668","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Meningioma in users of progestogen contraceptives: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS)"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9583-9105","authenticated-orcid":false,"given":"Richard H.","family":"Woods","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"3900_CR1","first-page":"1","volume":"62","author":"K Daniels","year":"2013","unstructured":"Daniels K, Mosher WD (2013) Contraceptive methods women have ever used: United States, 1982\u20132010. Natl Health Stat Rep 62:1\u201315","journal-title":"Natl Health Stat Rep"},{"issue":"12","key":"3900_CR2","doi-asserted-by":"publisher","first-page":"689","DOI":"10.3949\/ccjm.88a.20110","volume":"88","author":"S Vegunta","year":"2021","unstructured":"Vegunta S, Carrubba AR, Wasson MN (2021) Changing US trends in contraceptive choices. Cleve Clin J Med 88(12):689\u2013695. https:\/\/doi.org\/10.3949\/ccjm.88a.20110","journal-title":"Cleve Clin J Med"},{"issue":"4","key":"3900_CR3","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1166\/asl.2017.9121","volume":"23","author":"L Dewata","year":"2017","unstructured":"Dewata L, Prasetyo B, Yuliati A, Wahyuhadi J (2017) Hormonal contraceptive exposure and risk factors for meningioma in Soetomo Hospital 2012\u20132016. Adv Sci Lett 23(4):3291\u20133294. https:\/\/doi.org\/10.1166\/asl.2017.9121","journal-title":"Adv Sci Lett"},{"issue":"9","key":"3900_CR4","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1111\/ene.15423","volume":"29","author":"L Hoisnard","year":"2022","unstructured":"Hoisnard L, Laanani M, Passeri T et al (2022) Risk of intracranial meningioma with three potent progestogens: a population-based case\u2013control study. Eur J Neurol 29(9):2801\u20132809. https:\/\/doi.org\/10.1111\/ene.15423","journal-title":"Eur J Neurol"},{"key":"3900_CR5","doi-asserted-by":"publisher","unstructured":"Roland N, Neumann A, Hoisnard L et al (2024) Use of progestogens and the risk of intracranial meningioma: national case-control study. BMJ. e078078. https:\/\/doi.org\/10.1136\/bmj-2023-078078. Published online March 27, 2024","DOI":"10.1136\/bmj-2023-078078"},{"issue":"19","key":"3900_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16193362","volume":"16","author":"RL Griffin","year":"2024","unstructured":"Griffin RL (2024) The association between medroxyprogesterone acetate exposure and meningioma. Cancers 16(19):3362. https:\/\/doi.org\/10.3390\/cancers16193362","journal-title":"Cancers"},{"key":"3900_CR7","unstructured":"U.S. Food and Drug Administration (2025) FDA Adverse Event Reporting System (FAERS) quarterly data extract files. https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html. Accessed 5 Jan, 2025"},{"key":"3900_CR8","doi-asserted-by":"publisher","unstructured":"Poluzzi E, Raschi E, Piccinni C, De Ponti F (2012) Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA Adverse Event Reporting System (AERS). In: Karahoca A (ed) Data mining applications in engineering and medicine. InTech. https:\/\/doi.org\/10.5772\/50095","DOI":"10.5772\/50095"},{"issue":"Supplement_3","key":"3900_CR9","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","volume":"23","author":"QT Ostrom","year":"2021","unstructured":"Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2021) Cbtrus statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014\u20132018. Neuro-Oncol 23(Supplement_3):iii1\u2013iii105. https:\/\/doi.org\/10.1093\/neuonc\/noab200","journal-title":"Neuro-Oncol"},{"key":"3900_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.668765","volume":"12","author":"C Khouri","year":"2021","unstructured":"Khouri C, Nguyen T, Revol B et al (2021) Leveraging the variability of pharmacovigilance disproportionality analyses to improve signal detection performances. Front Pharmacol 12:668765. https:\/\/doi.org\/10.3389\/fphar.2021.668765","journal-title":"Front Pharmacol"},{"issue":"1","key":"3900_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP Van Puijenbroek","year":"2002","unstructured":"Van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11(1):3\u201310. https:\/\/doi.org\/10.1002\/pds.668","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"3900_CR12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B et al (2024) The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement. Drug Saf 47(6):575\u2013584. https:\/\/doi.org\/10.1007\/s40264-024-01421-9","journal-title":"Drug Saf"},{"issue":"6","key":"3900_CR13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B et al (2024) The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): explanation and elaboration. Drug Saf 47(6):585\u2013599. https:\/\/doi.org\/10.1007\/s40264-024-01423-7","journal-title":"Drug Saf"},{"key":"3900_CR14","doi-asserted-by":"publisher","unstructured":"Lawrie TA, Helmerhorst FM, Maitra NK, Kulier R, Bloemenkamp K, G\u00fclmezoglu AM. Types of progestogens in combined oral contraception: effectiveness and side-effects. Cochrane Fertility Regulation Group, ed. Cochrane Database Syst Rev. Published online May 11, 2011. https:\/\/doi.org\/10.1002\/14651858.CD004861.pub2","DOI":"10.1002\/14651858.CD004861.pub2"},{"issue":"6","key":"3900_CR15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/0026-0495(75)90044-X","volume":"24","author":"JM Stock","year":"1975","unstructured":"Stock JM, Ghatak NR, Oppenheimer JH (1975) Unsuspected meningioma in a patient with pituitary gigantism. Case report with autopsy findings. Metabolism 24(6):767\u2013775. https:\/\/doi.org\/10.1016\/0026-0495(75)90044-X","journal-title":"Metabolism"},{"issue":"4","key":"3900_CR16","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1080\/026886900417388","volume":"14","author":"E Hensiek","year":"2000","unstructured":"Hensiek E, Kellerman AJ, Hill JT (2000) Spontaneous regression of a solitary cerebral metastases in renal carcinoma followed by meningioma development under medroxyprogesterone acetate therapy. Br J Neurosurg 14(4):354\u2013356. https:\/\/doi.org\/10.1080\/026886900417388","journal-title":"Br J Neurosurg"},{"issue":"6","key":"3900_CR17","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.surneu.2006.11.063","volume":"68","author":"E Pozzati","year":"2007","unstructured":"Pozzati E, Zucchelli M, Schiavina M, Contini P, Foschini MP (2007) Rapid growth and regression of intracranial meningiomas in lymphangioleiomyomatosis: case report. Surg Neurol 68(6):671\u2013674. https:\/\/doi.org\/10.1016\/j.surneu.2006.11.063","journal-title":"Surg Neurol"},{"issue":"23","key":"3900_CR18","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1056\/NEJMc071938","volume":"357","author":"R Gazzeri","year":"2007","unstructured":"Gazzeri R, Galarza M, Gazzeri G (2007) Growth of a meningioma in a transsexual patient after estrogen\u2013progestin therapy. N Engl J Med 357(23):2411\u20132412. https:\/\/doi.org\/10.1056\/NEJMc071938","journal-title":"N Engl J Med"},{"issue":"5","key":"3900_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2176\/nmc.48.227","volume":"48","author":"J Shimizu","year":"2008","unstructured":"Shimizu J, Matsumoto M, Yamazaki E, Yasue M (2008) Spontaneous regression of an asymptomatic meningioma associated with discontinuation of progesterone agonist administration. Neurol Med Chir (Tokyo) 48(5):227\u2013230. https:\/\/doi.org\/10.2176\/nmc.48.227","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"3900_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n37","volume":"372","author":"A Weill","year":"2021","unstructured":"Weill A, Nguyen P, Labidi M et al (2021) Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study. BMJ 372:n37. https:\/\/doi.org\/10.1136\/bmj.n37","journal-title":"BMJ"},{"issue":"3","key":"3900_CR21","first-page":"193","volume":"136","author":"M Poisson","year":"1980","unstructured":"Poisson M, Magdelenat H, Foncin JF et al (1980) Estrogen and progestin receptors in meningiomas: a study in 22 cases (author\u2019s transl). Rev Neurol (Paris) 136(3):193\u2013203","journal-title":"Rev Neurol (Paris)"},{"key":"3900_CR22","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1016\/j.wneu.2020.04.168","volume":"140","author":"S Portet","year":"2020","unstructured":"Portet S, Banor T, Bousquet J et al (2020) New insights into expression of hormonal receptors by meningiomas. World Neurosurg 140:e87\u2013e96. https:\/\/doi.org\/10.1016\/j.wneu.2020.04.168","journal-title":"World Neurosurg"},{"key":"3900_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.611218","volume":"11","author":"F Maiuri","year":"2021","unstructured":"Maiuri F, Mariniello G, De Divitiis O et al (2021) Progesterone receptor expression in meningiomas: pathological and prognostic implications. Front Oncol 11:611218. https:\/\/doi.org\/10.3389\/fonc.2021.611218","journal-title":"Front Oncol"},{"issue":"1","key":"3900_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.37897\/RJN.2024.1.11","volume":"23","author":"MJ Mohammed","year":"2024","unstructured":"Mohammed MJ, Mohsin HI, Ali HS, Albayati AF (2024) Pathological implication of progesterone receptor expression in patients diagnosed with meningioma. Rom J Neurol 23(1):64\u201368. https:\/\/doi.org\/10.37897\/RJN.2024.1.11","journal-title":"Rom J Neurol"},{"issue":"1","key":"3900_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3171\/jns.1986.65.1.0099","volume":"65","author":"JJ Olson","year":"1986","unstructured":"Olson JJ, Beck DW, Schlechte J, Loh PM (1986) Hormonal manipulation of meningiomas in vitro. J Neurosurg 65(1):99\u2013107. https:\/\/doi.org\/10.3171\/jns.1986.65.1.0099","journal-title":"J Neurosurg"},{"issue":"9","key":"3900_CR26","first-page":"2604","volume":"50","author":"JW Koper","year":"1990","unstructured":"Koper JW, Foekens JA, Braakman R, Lamberts SW (1990) Effects of progesterone on the response to epidermal growth factor and other growth factors in cultured human meningioma cells. Cancer Res 50(9):2604\u20132607","journal-title":"Cancer Res"},{"issue":"5","key":"3900_CR27","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3171\/jns.1985.62.5.0757","volume":"62","author":"JR Jay","year":"1985","unstructured":"Jay JR, MacLaughlin DT, Riley KR, Martuza RL (1985) Modulation of meningioma cell growth by sex steroid hormones in vitro. J Neurosurg 62(5):757\u2013762. https:\/\/doi.org\/10.3171\/jns.1985.62.5.0757","journal-title":"J Neurosurg"},{"issue":"1","key":"3900_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/01616412.1989.11739853","volume":"11","author":"F Maiuri","year":"1989","unstructured":"Maiuri F, Montagnani S, Gallicchio B, Carandente M, Lanza GG, D\u2019Andrea F (1989) Oestrogen and progesterone sensitivity in cultured meningioma cells. Neurol Res 11(1):9\u201313. https:\/\/doi.org\/10.1080\/01616412.1989.11739853","journal-title":"Neurol Res"},{"issue":"1","key":"3900_CR29","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/00003643-199801000-00019","volume":"15","author":"K Ismail","year":"1998","unstructured":"Ismail K, Coakham HB, Walters FJM (1998) Intracranial meningioma with progesterone positive receptors presenting in late pregnancy. Eur J Anaesthesiol 15(1):106\u2013109. https:\/\/doi.org\/10.1097\/00003643-199801000-00019","journal-title":"Eur J Anaesthesiol"},{"issue":"1","key":"3900_CR30","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.surneu.2003.07.007","volume":"62","author":"OE Idowu","year":"2004","unstructured":"Idowu OE, Shokunbi MT, Amanor-Boadu SD, Roberts OA, Eyo C (2004) Surgical management of tuberculum sellae meningioma in a patient with a twin pregnancy: case report. Surg Neurol 62(1):60\u201363. https:\/\/doi.org\/10.1016\/j.surneu.2003.07.007","journal-title":"Surg Neurol"},{"issue":"1","key":"3900_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3171\/2014.12.JNS142112","volume":"124","author":"J Kerschbaumer","year":"2016","unstructured":"Kerschbaumer J, Freyschlag CF, Stockhammer G et al (2016) Hormone-dependent shrinkage of a sphenoid wing meningioma after pregnancy: case report. J Neurosurg 124(1):137\u2013140. https:\/\/doi.org\/10.3171\/2014.12.JNS142112","journal-title":"J Neurosurg"},{"issue":"1","key":"3900_CR32","doi-asserted-by":"publisher","first-page":"9153","DOI":"10.1038\/s41598-021-88742-2","volume":"11","author":"J Pettersson-Segerlind","year":"2021","unstructured":"Pettersson-Segerlind J, Mathiesen T, Elmi-Terander A et al (2021) The risk of developing a meningioma during and after pregnancy. Sci Rep 11(1):9153. https:\/\/doi.org\/10.1038\/s41598-021-88742-2","journal-title":"Sci Rep"},{"issue":"2","key":"3900_CR33","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqab259","volume":"163","author":"M Hage","year":"2022","unstructured":"Hage M, Plesa O, Lemaire I, Raffin Sanson ML (2022) Estrogen and progesterone therapy and meningiomas. Endocrinology 163(2):bqab259. https:\/\/doi.org\/10.1210\/endocr\/bqab259","journal-title":"Endocrinology"},{"issue":"18","key":"3900_CR34","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.18.1938","volume":"166","author":"CD Furberg","year":"2006","unstructured":"Furberg CD, Levin AA, Gross PA, Shapiro RS, Strom BL (2006) The FDA and drug safety: a proposal for sweeping changes. Arch Intern Med 166(18):1938. https:\/\/doi.org\/10.1001\/archinte.166.18.1938","journal-title":"Arch Intern Med"},{"issue":"7","key":"3900_CR35","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14740338.2017.1323867","volume":"16","author":"YM Alatawi","year":"2017","unstructured":"Alatawi YM, Hansen RA (2017) Empirical estimation of under-reporting in the U.S. food and drug administration adverse event reporting system (FAERS). Expert Opin Drug Saf 16(7):761\u2013767. https:\/\/doi.org\/10.1080\/14740338.2017.1323867","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"3900_CR36","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","volume":"74","author":"JL Faillie","year":"2019","unstructured":"Faillie JL (2019) Case\u2013non-case studies: principle, methods, bias and interpretation. Therapies 74(2):225\u2013232. https:\/\/doi.org\/10.1016\/j.therap.2019.01.006","journal-title":"Therapies"},{"issue":"6","key":"3900_CR37","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/pds.3979","volume":"25","author":"TJ Moore","year":"2016","unstructured":"Moore TJ, Furberg CD, Mattison DR, Cohen MR (2016) Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014. Pharmacoepidemiol Drug Saf 25(6):713\u2013718. https:\/\/doi.org\/10.1002\/pds.3979","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"3900_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40264-024-01473-x","volume":"48","author":"Y Noguchi","year":"2025","unstructured":"Noguchi Y, Tachi T, Yoshimura T (2025) Caveats of covariate adjustment in disproportionality analysis for best practices. Drug Saf 48(1):1\u20135. https:\/\/doi.org\/10.1007\/s40264-024-01473-x","journal-title":"Drug Saf"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03900-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03900-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03900-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:21:50Z","timestamp":1759994510000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03900-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3900"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03900-z","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not involve human subjects and was determined to be exempt from formal review by the Emory University Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Portions of the present work were undertaken and submitted in partial satisfaction of RHW\u2019s Master of Public Health thesis requirement at Emory University Rollins School of Public Health. RHW is an employee at a law firm that specializes in complex product liability litigation. Certain partners at the law firm have been appointed to leadership positions in a multidistrict litigation (MDL No. 3140) in which certain manufactures of medroxyprogesterone-containing medications have been named as defendants. The firm is not currently involved in litigation associated with any other medications included in this study. The firm had no role in the concept, design or conduct of this study, did not have input on the contents of the manuscript and does not endorse the results or conclusions presented therein.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}